Glutamine and glutamate are known to play important roles in cancer biology. However, no detailed information is available in terms of their levels of involvement in various biological processes across different cancer types, whereas such knowledge could be critical for understanding the distinct characteristics of different cancer types. Our computational study aimed to examine the functional roles of glutamine and glutamate across different cancer types. We conducted a comparative analysis of gene expression data of cancer tissues versus normal control tissues of 11 cancer types to understand glutamine and glutamate metabolisms in cancer. Specifically, we developed a linear regression model to assess differential contributions by glutamine and/or glutamate to each of seven biological processes in cancer versus control tissues. While our computational predictions were consistent with some of the previous observations, multiple novel predictions were made: (1) glutamine is generally not involved in
Data & statistics on Incidence Rates for Major Cancer Sites by Gender: Estimated Age-Standardized Incidence Rates for Major Cancer Sites by Gender and Province, Canada, 2002, Incidence Rates for Major Cancer Sites by Gender, Estimated Age-Standardized Incidence Rates for Major Cancer Sites by Sex and Province, Canada, 2006...
Cancer researchers warned Monday that the number of elderly cancer patients would likely double from 2000 to 2030, creating huge challenges to healthcare systems worldwide.
TY - JOUR. T1 - Glypican 3 expression in pediatric malignant solid tumors. AU - Kinoshita, Yoshiaki. AU - Tanaka, Sakura. AU - Souzaki, Ryota. AU - Miyoshi, Kina. AU - Kohashi, Kenichi. AU - Oda, Yoshinao. AU - Nakatsura, Tetsuya. AU - Taguchi, Tomoaki. PY - 2015/2. Y1 - 2015/2. N2 - Purpose Glypican 3 (GPC3) is one of the cell surface heparan sulfate proteoglycans that binds to the cell membrane, and it is known as an oncofetal protein in adult malignant tumors. Clinical trials using a GPC3 peptide vaccine have already been started in Japan as a new immunotherapy for hepatocellular carcinoma in adult patients. To investigate the possibility of GPC3 immunotherapy for pediatric malignant tumors, we assessed the expression of GPC3 in pediatric malignant tumors. Methods Immunohistochemically, the GPC3 expression was examined in 159 pediatric solid tumors, including 35 cases of neuroblastoma, 30 cases of Wilms tumor, 10 cases of hepatoblastoma, 25 cases of germ cell tumors, 56 cases of ...
The subject carries the diagnosis of malignant solid tumor or a malignant or non-malignant hematologic disorder, and is being screened at the NIH for eligibility for an NIH Clinical Center treatment protocol.. OR. The subject carries the diagnosis of malignant solid tumor or a malignant or non-malignant hematologic disorder, and is already enrolled on a clinical protocol at the NIH Clinical Center.. OR. The subject is a related HLA-compatible family member of a patient (bearing a diagnosis of malignant solid tumor or a malignant or non-malignant hematologic) being evaluated for or already enrolled on a clinical protocol at the NIH Clinical Center and is identified as a potentially suitable donor of allogeneic hematopoietic stem cells for transplantation.. OR. The subject carries the diagnosis of malignant solid tumor or a malignant or non malignant hematologic disorder or a bone marrow failure condition and is not available to participate in an NIH Clinical Center treatment protocol, or travel ...
This pharmacokinetic study of nivolumab showed that there is little ethnic difference in the handling of nivolumab.Nivolumab was well tolerated in Korean patients.Background.This phase I study of nivolumab, an anti‐programmed cell death‐1 (anti‐PD‐1) monoclonal antibody, investigated the pharmacokinetics and safety of nivolumab in Korean patients with advanced solid tumors. Findings were compared with results from Japan and the U.S.Materials and Methods.In this two‐part study, patients received a single dose of nivolumab (1, 3, and 10 mg/kg; ONO‐4538‐13) and were followed up for 3 weeks. Those who met the required criteria proceeded to the second part (ONO‐4538‐14), and received the same dose as in part one every 2 weeks.Results.Six patients per dose level were enrolled (n = 18). The mean elimination half‐life of nivolumab among the groups ranged from 15.0 to 19.1 days. The maximum serum concentration and area under serum concentration-time curve increased almost ...
One of the things we do is we are part of the WHO specialised agency for cancer and for the last fifty years weve been developing statistics on the global burden of cancer. One of the key pieces that we work with WHO on is to develop the statistics and understand the future cancer burden as well. So we know there is going to be something in the order of thirty million new cancer cases by 2035, currently its about 14.1 million new cases. So the scale of cancer is increasing greatly, partially because of demographic effects, the impact of population aging and growth, but also increasing risk and the changing profile of cancers as well.. Thats important that we know that but we really need also local data and the best way to get better global data as well as local data is to support cancer surveillance, both in terms of incidence and mortality. We are buoyed by the high level impetus that we see for NCDs and cancers and governments now trying to tackle the increasing burden from NCDs and cancer. ...
Folakemi Odedina, Ph.D., a professor of pharmacy and the director of the UF Shands Cancer Centers Cancer Health Disparities Program, served on the planning committee for National Cancer Institute Global Cancer Research Day, which was held in Washington, DC in March in conjuction with the Consortium of Universities for Global Health Annual Meeting.. The meeting aimed to engage a diverse range of participants including both cancer researchers and global health professionals who may not necessarily have specific cancer expertise, but have an interest in exploring the intersection between global health and cancer. The Global Cancer Research Day meeting utilized a highly interactive format to engage the cancer research and global health communities in a rich dialogue about cross-cutting issues. Topics explored included capacity building, cancers related to infectious diseases (including HIV-related malignancies), lessons learned in global health and tapping into the global health communitys ...
Despite deep cuts in federal research spending due to sequestration, Associate Professor Muhammad Zaman (BME, MSE) has secured a five-year grant of more than $3 million from the National Institutes of Health to develop mathematical and computational models of how breast cancer cells move and communicate as they migrate from tumors, invade nearby tissue and proliferate.. By mapping this process from the molecular to the cellular level through detailed, comprehensive multiscale models based on strong experimental and computational data, Zaman and his collaborators-MIT Professors Frank Gertler, Roger Kamm and Douglas Lauffenberger, and a computational modeling team in Singapore-aim to uncover new pathways to control tumor development and metastasis in the breast, lung, and other organs.. Complex biochemical and biomechanical interactions govern how cancer cells spread from tumors and metastasize in nearby tissue. Much is known about the mechanics of how cancer cells migrate, but how biochemical ...
Purpose: To determine the maximum tolerated dose, dose-limiting toxicity (DLT), and recommended phase II dose of dasatinib in metastatic solid tumors refractory to standard therapies or for which no effective standard therapy exists.. Experimental Design: In this phase I, open-label, dose-escalation study, patients received 35 to 160 mg of dasatinib twice daily in 28-day cycles either every 12 hours for 5 consecutive days followed by 2 nontreatment days every week (5D2) or as continuous, twice-daily (CDD) dosing.. Results: Sixty-seven patients were treated (5D2, n = 33; CDD, n = 34). The maximum tolerated doses were 120 mg twice daily 5D2 and 70 mg twice daily CDD. DLTs with 160 mg 5D2 were recurrent grade 2 rash, grade 3 lethargy, and one patient with both grade 3 prolonged bleeding time and grade 3 hypocalcemia; DLTs with 120 mg twice daily CDD were grade 3 nausea, grade 3 fatigue, and one patient with both grade 3 rash and grade 2 proteinuria. The most frequent treatment-related toxicities ...
Cancer therapies are designed to kill tumour cells, but produce tumour cell debris in the process.. In a study published in The Journal of Experimental Medicine, researchers from Brigham and Womens Hospital and colleagues show that leftover debris can stimulate inflammation and tumour growth, but that molecules called resolvins can block that unwanted inflammatory response.. The findings point towards a new way to enhance the effectiveness of current cancer therapies and potentially prevent tumour recurrence.. When conventional cancer treatments, such as radiation or chemotherapy drugs, break apart tumours, they can also spread and stimulate the production of proinflammatory cytokines.. These signalling molecules, known to promote tumour growth, were at the centre of the investigation.. "Dead and dying tumour cells are an under-appreciated component of the tumour microenvironment that may promote tumour progression," said Professor Charles Serhan, PhD, DSc, Department of Anesthesiology, ...
Current Cancer Therapy Reviews publishes frontier reviews, original research articles, drug clinical trial studies and guest edited thematic issues on all the latest advances in clinical oncology, cancer therapy and pharmacology. The journals aim is to publish the highest quality review articles dedicated to clinical research in the field. The journal is essential reading for all researchers and clinicians in cancer therapy.
Weve shown that an aged immune system can combat cancer just as well as a young one if you remove the impediments to successful immunity, which are different that those in younger hosts," Dr. Curiel said. "Weve shown that if you test all your immune therapy just in young mice and young people, youll never learn how it works in older patients - the ones most at risk for cancer. You might conclude that drugs dont work in aged hosts, when they do. But they have to be combined with some help.". After discovering this in melanoma, the researchers then looked at whether the same action held true in colon cancer, a major cancer killer in the elderly.. "The details were different in colon cancer. The bad immune cells that increased in the aged mice and how they were knocked down by the drugs were different than in melanoma," Dr. Curiel said. "But the result was the same - we identified a drug combination that was highly effective in the aged mice.". That means that not only must this strategy be ...
Many of the worlds top cancer researchers presented the latest in cancer research when the Centre for Cancer Biomarkers invited to a two-day symposium at Solstrand.
... American Association for Cancer Research Aims to Raise Awareness a...PHILADELPHIA Sept. 24 /- ...News facts: ...-- Most Americans with cancer would be receptive to participating in...,Video:,The,Looming,Crisis,in,Cancer,Drug,Development:,97%,of,Adult,Cancer,Patients,Do,Not,Take,Advantage,of,Clinical,Trial,Programs,medicine,advanced medical technology,medical laboratory technology,medical device technology,latest medical technology,Health
Patient accrual. A phase I, single center, open-label design was used to assess the safety, PK characteristics, and efficacy of 2ME2. This study was conducted at the University of Wisconsin Paul P. Carbone Comprehensive Cancer Center after institutional review board approval. Patients ages ,18 y, with biopsy-proven disease, a life expectancy of ,3 mo, Karnofsky performance status of ,80%, and unresectable or metastatic solid malignancy were eligible. Patients were required to have either progressed on a previous therapy or to lack effective treatment options. Inclusion criteria included at least one measurable lesion as defined by the Response Evaluation Criteria in Solid Tumors (15) or, in the case of patients with prostate cancer, an increasing serum level of prostate-specific antigen.. Exclusion criteria excluded hematopoietic (Hgb, ,10 g/dL; platelets, ,75,000/mm3), hepatic (aspartate aminotransferase or ALT of ,2.5 times the upper limit of normal) or renal (Cr of ,1.5 times upper limit of ...
Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, ...
This said, however, it is clear that work remains to be done in improving late effects. This may mean modifying current cancer treatments to reduce their neurotoxicity, or introducing new therapies and interventions for survivors. For those interested in developing new intervention strategies, the CCSS data is likely to prove an excellent starting point.. "Findings from this study indicate that current therapies, with the continued goal of 100% cure, may still result in poor perceived health outcomes, and more work is needed to address these toxicities in treatment," says Ness. "For those who develop adverse outcomes, rehabilitation strategies that work in other populations with pain and mobility limitations may be effective and need to be tested.". Already, several randomised intervention studies have been completed off the back of CCSS-based research. Having recruited a cohort of high-risk childhood cancer survivors, these studies looked into the benefits of breast cancer screening, ...
New research finds that gut bacteria affect cancer risk; in particular, an unhealthy gut flora balance may contribute to colorectal cancer.
Kulimova, Emma et al "Growth inhibition and induction of apoptosis in acute myeloid leukemia cells by new indolinone derivatives targeting fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor receptors." Molecular Cancer Therapeutics 5.12 (2006): 3105-3112. Web. 04 July. 2020. ...
Thank you for sharing this Molecular Cancer Therapeutics article.. NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.. ...
The purpose of this study is to develop and pilot test a behavioral intervention for elderly adults in treatment for colon cancer, to enhance their skills for managing the challenges of completing chemotherapy regimens. The investigators will assess feasibility and acceptability of the intervention, and explore preliminary efficacy of the intervention for reducing psychological distress and improving rates of optimal chemotherapy adherence ...
The relationship between diet and exercise and its positive effects on treatment outcomes in obese cancer patients has sparked interest for quite some time, but for paediatric patients, the research has been limited.. While healthy eating is encouraged during and after treatment, special diet interventions as part of treatment for paediatric patients are uncommon.. Additionally, when it comes to physical activity, clinicians are cautious about administering an exercise regimen in a cancer care setting.. "The purpose of the review was to delineate between obesity reduction as a goal for energy balance interventions versus simply changing diet or adding exercise," said Joya Chandra, Ph.D., associate professor of Paediatric Research and lead author on the study.. "For example, our review confirmed modifying diet or adding moderate exercise can improve chemotherapy efficacy independent of weight loss.". Obesity, an epidemic and risk factor for several cancers, is on the rise in paediatric cancer ...
Background: Both dietary and serum levels of inorganic phosphate (Pi) have been linked to development of cancer in experimental studies. This is the first population-based study investigating the relation between serum Pi and risk of cancer in humans. Methods: From the Swedish Apolipoprotein Mortality Risk (AMORIS) study, we selected all participants (,20 years old) with baseline measurements of serum Pi, calcium, alkaline phosphatase, glucose, and creatinine (n = 397,292). Multivariable Cox proportional hazards regression analyses were used to assess serum Pi in relation to overall cancer risk. Similar analyses were performed for specific cancer sites. Results: We found a higher overall cancer risk with increasing Pi levels in men (HR: 1.02 (95% CI: 1.00-1.04) for every SD increase in Pi), and a negative association in women (HR: 0.97 (95% CI: 0.96-0.99) for every SD increase in Pi). Further analyses for specific cancer sites showed a positive link between Pi quartiles and the risk of cancer of ...
Jolly, Mohit Kumar et al "E-cadherin represses anchorage-independent growth in sarcomas through both signaling and mechanical mechanisms." Molecular Cancer Research (2019): molcanres.0763.2018. Web. 22 Jan. 2020. ...
Gentaur molecular products has all kinds of products like :Biochai , Biochai \ cDNA Panel _ Human Tumor Tissue, Different Tumor Type, Different Donors \ C8235547 for more molecular products just contact us
New research published in Diabetologia reveals that type 1 diabetes is associated with an increased risk of various cancer types including cancers of the stomach, liver, pancreas, endometrium, ovary and kidney, but a reduced risk of other cancer types, including prostate and breast cancer. The study analysed more than 9000 cancer cases in type 1 diabetes patients diagnosed across five countries, using data from five nationwide diabetes registers: Australia (2000-2008), Denmark (1995-2014), Finland (1972-2012), Scotland (1995-2012) and Sweden (1987-2012). Using the data of those in national cancer registries, the authors were able to compare the cancer incidence among people with type 1 diabetes to that of the general population. "The analyses across all cancers combined revealed no increased overall cancer risk among men with type 1 diabetes, whereas women with type 1 diabetes experienced a 7% increased overall cancer risk. The neutral overall cancer risk among men with type 1 diabetes was ...
Constipation in advanced cancer • Delirium in Adult Cancer • Diarrhoea in adult cancer patients Patients • Management of anaemia and iron deficiency in patients with cancer • Management of infusion reactions to systemic anticancer therapy • Management of toxicities from immunotherapy • Management of febrile neutropaenia • MASCC and ESMO consensus guidelines for the prevention of chemotherapy and radiotherapy-induced nausea and vomiting • Treatment of dyspnoea in advanced cancer patients • Central venous access in oncology • Management of oral and gastrointestinal mucosal injury • Management of refractory symptoms at the end of life and the use of palliative sedation • Advanced care planning in palliative care • Bone health in cancer patients • Cancer, fertility and pregnancy • Management of chemotherapy extravasation • Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy • Management of cancer pain • Management of venous ...
Constipation in advanced cancer • Delirium in Adult Cancer • Diarrhoea in adult cancer patients Patients • Management of anaemia and iron deficiency in patients with cancer • Management of infusion reactions to systemic anticancer therapy • Management of toxicities from immunotherapy • Management of febrile neutropaenia • MASCC and ESMO consensus guidelines for the prevention of chemotherapy and radiotherapy-induced nausea and vomiting • Treatment of dyspnoea in advanced cancer patients • Central venous access in oncology • Management of oral and gastrointestinal mucosal injury • Management of refractory symptoms at the end of life and the use of palliative sedation • Advanced care planning in palliative care • Bone health in cancer patients • Cancer, fertility and pregnancy • Management of chemotherapy extravasation • Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy • Management of cancer pain • Management of venous ...
Health,...SAN DIEGO Oct. 6 /- bioTheranostics a bioMerieux compan...Under the terms of the agreement UK-based Lab21 will market the THERO...The CTID assay is a 92-gene molecular cancer classifier that identifie... We recognize a tremendous need globally for new technologies that wil...,bioTheranostics,Announces,Commercial,Agreement,With,Lab21,to,Market,THEROS,CancerTYPE,ID(R),Molecular,Cancer,Classifier,in,United,Kingdom,,Ireland,and,Middle,East,Countries,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
The BRAF protein kinase is widely studied as a cancer driver and therapeutic target. However, the regulation of its expression is not completely understood. Taking advantage of the RNA-seq data of more than 4800 patients belonging to 9 different cancer types, we show that BRAF mRNA exists as a pool of 3 isoforms (reference BRAF, BRAF-X1, and BRAF-X2) that differ in the last part of their coding sequences, as well as in the length (BRAF-ref: 76 nt; BRAF-X1 and BRAF-X2: up to 7 kb) and in the sequence of their 3UTRs. The expression levels of BRAF-ref and BRAF-X1/X2 are inversely correlated, while the most prevalent among the three isoforms varies from cancer type to cancer type. In melanoma cells, the X1 isoform is expressed at the highest level in both therapy-naïve cells and cells with acquired resistance to vemurafenib driven by BRAF gene amplification or expression of the Δ[3-10] splicing variant. In addition to the BRAF-ref protein, the BRAF-X1 protein (the full length as well as the Δ[3-10]
Restricted Access Oops, it looks like you dont have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following. ...
Cancer/testis (CT) genes have expression normally restricted to the testis, but become activated during oncogenesis, so they have excellent potential as cancer-specific biomarkers. Evidence is starting to emerge to indicate that they also provide function(s) in the oncogenic programme. Human TEX19 is a recently identified CT gene, but a functional role for TEX19 in cancer has not yet been defined. siRNA was used to deplete TEX19 levels in various cancer cell lines. This was extended using shRNA to deplete TEX19 in vivo. Western blotting, fluorescence activated cell sorting and immunofluorescence were used to study the effect of TEX19 depletion in cancer cells and to localize TEX19 in normal testis and cancer cells/tissues. RT-qPCR and RNA sequencing were employed to determine the changes to the transcriptome of cancer cells depleted for TEX19 and Kaplan-Meier plots were generated to explore the relationship between TEX19 expression and prognosis for a range of cancer types. Depletion of TEX19 levels in
A team of British scientists has shed more light on how cancer might be spread in the body, describing a so-called chase-and-run phenomenon involving malignant and healthy cells.
Founded in 1907, the American Association for Cancer Research is a professional society of more than 24,000 laboratory, translational, and clinical scientists engaged in all areas of cancer research in the United States and in more than 60 other countries. AACRs mission is to accelerate the prevention and cure of cancer through research, education, communication, and advocacy. Its principal activities include the publication of five major peer-reviewed scientific journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; and Cancer Epidemiology, Biomarkers & Prevention. AACRs Annual Meeting attracts more than 15,000 participants who share new and significant discoveries in the cancer field. Specialty meetings, held throughout the year, focus on the latest developments in all areas of cancer research. ...
Learn your options for getting pregnant once cancer treatment ends. Find out how cancer treatment can affect female fertility, and how to be proactive about your fertility before cancer treatment begins.
The primary objective of this clinical research study is to evaluate the safety, tolerability, and maximum tolerated dose (MTD) of intravenous (IV) MST-
Research indicates that physical activity not only helps prevent cancer (29, 30), it also confers mortality benefits for cancer survivors (31, 32). Yet, current cancer therapies do not address the association of lifestyle factors on prognosis and survivorship, despite the fact that obesity, weight gain, and physical inactivity are common in cancer patients before and after a cancer diagnosis (33). There is a strong association between having a higher body mass index (BMI) before cancer diagnosis and mortality from different cancer types. For instance, uterine cancer survivors who had a prediagnosis BMI greater than 35 have a 6-fold increase risk of mortality compared with survivors who had a prediagnosis BMI less than 25 (34). In early-stage breast cancer, a BMI greater than or equal to 40 is associated with at least a 5-fold increase of mortality risk compared with BMI less than 25 (35). Furthermore, a higher BMI may explain up to 14% and 20% of all deaths from cancer in men and women, ...
In what could be a major step forward in our understanding of how cancer moves around the body, researchers have observed the spread of cancer cells from the initial tumour to the bloodstream. The findings suggest that secondary growths called metastases punch their way through the walls of small blood vessels by targeting a molecule…
Cancer is a major health problem that can debilitate and destroy human lives. One out of every 4 deaths in the United States is caused by cancer. More than $124.6 billion was spent in direct medical costs for 13.7 million cancer survivors and 1.5 million newly diagnosed cancer patients in the United States in 2010. Increasing human life expectancy will inevitably raise cancer prevalence and the related costs. Consequently, the development of effective cancer prevention strategies is increasingly important. Histologically, the development of cancer involves multiple steps, which occur over several years after the initial carcinogen exposure from normal to hyperplasia, mild, moderate, and severe dysplasia, and carcinoma in situ, before finally progressing to invasive cancer (1). Throughout this long, multi-step developmental course, there is a wide scope of possible preventive approaches that can delay or prevent the development of cancer. Different cancer prevention strategies such as behavioral ...
WASHINGTON-The search for cancer prevention agents is hampered by the fact that only one biomarker-the prostate-specific antigen (PSA)-now offers a simple, noninvasive measure of the cancer process in the body, Robert W. Day, MD, PhD, said at a meeting of the Cancer Prevention Working Group, sponsored by the Cancer Research Foundation of America (CRFA). The need for cancer biomarkers is critical, not only for their diagnostic benefits but also to provide endpoints for judging the effectiveness of any proposed chemopreventive agents. 1
Cancer therapies are designed to kill tumor cells, but produce tumor cell debris in the process. In a study published in The Journal of Experimental Medicine, researchers from Brigham and Womens Hospital and colleagues show that leftover debris can stimulate inflammation and tumor growth, but that molecules called resolvins can block that unwanted inflammatory response. The findings point towards a new way to enhance the effectiveness of current cancer therapies and potentially prevent tumor recurrence.
Cancer researcher Tom Marsilje is racing to cure his colon cancer. His team iw working on a personalized vaccine to rev up his immune system.
Introduction: This measure comprises national data on the distribution of cancer stage at diagnosis for sixteen major childhood (paediatric) cancers. In 2018, Cancer Australia reported the first national data on stage at diagnosis for selected childhood cancers for children aged 0 -14 years, for the diagnostic period 2006−2010. This release presents more detailed information
How many proteins can be identified in a 2-DE gel spot within an analysis of a complex human cancer tissue proteome Electrophoresis , 2018, online Xianquan Zhan, Haiyan Yang, Fang Peng, Jianglin Li, Yun Mu, Ying Long, Tingting Cheng, Yuda Huang, Zhao Li, Miaolong Lu, Na Li, Maoyu Li, Jianping Liu and Peter R. Jungblut Abstract Two-dimensional gel...
A former University of Pennsylvania cancer researcher used Department of Defense research money to fund a for-profit business, according to an indictment by the U.S. Attorney for the Eastern District of Pennsylvania.
The primary objective of this study is to evaluate the safety and tolerability of ONO-7746 across multiple doses in patients with solid tumors and chemo
Molecular and cellular events that drive premalignant progression are on the verge of being comprehensively characterized in a report that lays out an agenda for the immediate future of cancer prevention research.
Study of MK-1454 Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced / Metastatic Solid Tumors or Lymphomas (MK-1454-001) - NCT03010176
Memorial Sloan Kettering researchers have found a naturally occurring compound that can destroy cancer cells in mice by targeting MYC, a cancer-causing gene that has remained elusive until now.
Memorial Sloan Kettering researchers have found a naturally occurring compound that can destroy cancer cells in mice by targeting MYC, a cancer-causing gene that has remained elusive until now.
Clinical trial for Solid Tumor | Lymphoma | Malignant neoplasm of brain | Neuroblastoma , Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors CNS Tumors or Lymphoma
A protein responsible for cancer-promoting cell signaling is also thought to keep the key component of its signalling pathway tied down and inactive, scientists suggest
Many cancer researchers lack access to affordable, well-characterized, and analytically validated renewable affinity reagents, a problem that could be hindering cancer biomarker discovery and validation, cancer diagnostics development, and therapeutics monitoring.
NaturalSociety, You can bet that polio vaccines will now be promoted since the Glaxo Smith Kline (accidental) dumping of live polio viruses into a Belgium lake.. On the same token, you can bet that forced Ebola vaccinations are just around the corner due to fear of Ebola spreading through the U.S., but do we really want to trust an industry which already puts carcinogenic adjuvants into the vaccines used to "treat" measles, mumps, polio, rubella, cervical cancer, and more? I doubt it.. Vaccines are full of adjuvants, compounds that are meant to enhance the specific immune response against co-inoculated antigens. The word comes from the Latin word adjuvare, which means to help or to enhance. But these adjuvants dont enhance anything but a compromised immune system.. Following are cancer-causing ingredients, neuro-toxins, and immune-destroying extras as well as some disturbing evidence as to the true intent behind vaccines overall.. Formaldehyde - This is classified as a known carcinogen. Both ...
A team of scientists, led by researchers at the University of California, San Diego School of Medicine, has shown for the first time how cancer cells control the ON/OFF switch of a program used by developing embryos to effectively metastasize in vivo, breaking free and spreading to other parts of the body, where they can proliferate and grow into secondary tumors.. The findings are published in the December 11 issue of the journal Cancer Cell.. In 90 percent of cancer deaths, it is the spreading of cancer, known as metastasis, which ultimately kills the patient by impacting ever-more tissues and functions until the body fails. Ten years ago, a French cancer researcher named Jean Paul Thiery hypothesized that tumor cells metastasized by exploiting a developmental process known as epithelial-to-mesenchymal transition or EMT.. EMT is seen in developing embryos whose cells transform from stationary epithelial cells into more mobile mesenchymal cells, the latter able to migrate to new locations and ...
Specialists at Mayo Clinic are among the nations leading cancer researchers. Cancer research is conducted in coordination with the Mayo Clinic Cancer Center. The Mayo Clinic Cancer Center receives funding from the National Cancer Institute and is designated as a comprehensive cancer center - recognition for an institutions scientific excellence and multidisciplinary resources focused on cancer prevention, diagnosis and treatment. ...
ACS: 1/29/13. This report provides the estimated numbers of new cancer cases and deaths for African Americans during 2013, as well as current statistics on cancer incidence, mortality, and survival. It also includes information on cancer risk factors such as tobacco use, physical inactivity, and use of cancer screening examinations. Read More. ...
The American Association for Cancer Research (AACR) issued congratulations to Allison S. Betof, MD, PhD, on her election to Chairperson-elect of the Associate Member Council (AMC) of AACR. Dr. Betof assumed office at the AACR Annual Meeting earlier this month and will serve as Chairperson-elect from 2017-2018. Dr. Betof is a medical oncology fellow at Memorial Sloan Kettering Cancer Center in New York. She will become AMC Chairperson in 2018-2019.. The Associate Member Council was established by AACR in 1993 to help in cultivating the next generation of cancer researchers. On behalf of the AACR, the Associate Member Council extended further congratulations to four other individuals elected to join the council this year. These new Council members also took office at the AACR Annual Meeting and will serve a 3-year term.. The four new members of the AMC selected to take office in April 2017 are Renée de Leeuw, PhD, Kelsey R. Hampton, BS, Robert T. Jones, BS, and Neil Vasan, MD.. Dr. de Leeuw is a ...
Many of todays medicines were discovered by trial and error: a substance is found which helps alleviate the symptoms of a disease, and it may take years before scientists really understand how it works. Typically they find that a drug has its effects by attaching itself to a particular molecule in a cell and blocking part of its activity, the way you might prevent someone from turning a light on or off by putting a lock over the switch. Scientists now hope to take the opposite approach, and custom-design drugs to block specific switches. To do so, they will need precise "technical diagrams" of the molecules they want to lock up. Now the Italian researcher Giulio Superti-Furga and his colleagues at the European Molecular Biology Laboratory (EMBL) have produced such a diagram of a cancer-causing molecule, and their work gives researchers a good idea of how to go about designing drugs. Their report appears in the current issue of the journal Cell.. ...
Background Integrin signaling is an attractive target for anti-cancer treatment. GLPG0187 is a broad spectrum integrin receptor antagonist (IRA). GLPG0187 inhibited tumor growth and metastasis in mouse models. Methods We aimed to determine the Recommended Phase II Dose (RP2D) and to assess safety and tolerability of continuous i.v. infusion in ... read more patients with advanced malignant solid tumors. Anticipated dose levels were 20, 40, 80, 160, 320, and 400 mg/day in a modified 3 + 3 design. Plasma concentrations of GLPG0187 were assessed to characterize the pharmacokinetics (PK). C-terminal telopeptide of type I collagen (CTX) was used as pharmacodynamics marker. Results Twenty patients received GLPG0187. No dose limiting toxicities (DLTs) were observed. The highest possible and tested dose was 400 mg/day. Fatigue was the most frequently reported side effect (25 %). Recurrent Port-A-Cath-related infections and skin toxicity suggest cutaneous integrin inhibition. No dose-dependent toxicity ...
Restricted Access Oops, it looks like you dont have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following. ...
The FDA is expanding its recall of some blood pressure and heart failure medications because traces of cancer-causing NDMA were found in valsartan-based medications.
11 Jan 2018. A team of cancer researchers from the University of Liverpool, has made an important contribution to our understanding of cancer cell regulation which could better inform future cancer treatments.. The research is funded by North West Cancer Research, which has ring-fenced £180,000 for the three year-long project which started in 2015.. Led by Professor Ian Prior at the University of Liverpool, in collaboration with researchers at AstraZeneca, the research focuses on a group of proteins found in the human body called kinases.. Their research measures how changes in kinase activity can influence the growth, development and regulation of cancer cells.. They measure kinase network rewiring that occurs in cancer patients so that they can identify new strategies for killing cancer cells.. Their insights into this important family of proteins have been published in the journal Cancer Research and will provide a foundation for future research on the use of kinases in cancer ...
The cover features an image of RNA sequencing (RNA-Seq) results for a processed transcript of the mucin 5AC gene (MUC5AC, foreground), a potentially important smoking- and lung cancer-related gene. The output is superimposed on an image of human ciliated columnar bronchial epithelial cells obtained by endoscopic brushings of the mainstem bronchi (100X, modified Wright-Giemsa stain). The MUC5AC read coverage plot displays reads aligning to the transcript normalized by the total number of reads on the y-axis versus the genomic coordinates on the x-axis. The MUC5AC processed transcript shows marked upregulation in healthy current smokers compared with never smokers and downregulation in smokers with lung cancer compared with smokers having benign lung disease. The detection of MUC5AC expression highlights the advantage of RNA-Seq because the transcript is not annotated in RefSeq and there are no probes on the Affymetrix Exon 1.0 ST microarray to interrogate it. RNA-Seq is one of several ...
A human gene called p53, which is commonly known as the "guardian of the genome," is widely known to combat the formation and progression of tumors. Yet, mutant forms of p53 have been linked to more cases of human cancer than any other gene.. Investigating core mechanisms of how cancer cells respond to their surroundings in the human body, biologists at the University of California San Diego have discovered new evidence about mutant p53 that may reshape our understanding of tumor growth and ultimately how we treat cancer.. A study published in the journal Nature Communications led by Homa Rahnamoun in Shannon Lauberths laboratory at UC San Diegos Division of Biological Sciences uncovered a new mechanism linking mutant p53 function to chronic inflammation-a long-term condition typically associated with a response in the bodys immune system-which can be induced in situations ranging from stress to food consumption. Lauberth said increasing evidence supports the role of chronic inflammation in ...
Childhood cancer remains the leading cause of death by disease among children in the United States. Every day, 42 children are diagnosed with cancer and the average age of diagnosis is 6. Cancer affects all ethnic, gender, and socio-economic groups and more than 40,000 children undergo treatment for cancer each year. [Source: CureSearch]. The causes of childhood cancers are largely unknown, and for the most part they cannot be prevented. A few conditions, such as Down syndrome, other specific chromosomal and genetic abnormalities, and ionizing radiation exposures, explain a small percentage of cases. Children with AIDS have an increased risk of developing certain cancers, predominantly non-Hodgkin lymphoma and Kaposi sarcoma. [Source: CureSearch]. The average age of death for a child with cancer is 8, causing a child to lose 69 years of expected life. [Source: Kids V Cancer]. Incidence of invasive pediatric cancers is up 29% in the past 20 years. [Source: Kids V Cancer]. The National Cancer ...
Posted on 28 February 2017. Scientists at the Universities of York and Huddersfield have improved understanding of a molecule that destroys cancerous tumours without harming healthy cell tissue.. The discovery opens up the potential for highly effective new cancer treatments that are free of serious side effects.. The research team has developed and patented a cancer treatment regime that exploits the unique properties of the molecule - a protein named Cluster of Differentiation 40 (CD40).. Professor Jenny Southgate said: "Most cancer therapies are toxic to all cells and finding a therapy that can kill cancer cells selectively whilst sparing a patients normal cells is the Holy Grail for cancer researchers. By using the urothelial research platform developed by our team, we were able to discover how one promising drug target, called CD40, is able to distinguish between normal and cancer cells, resulting in cancer cell death.". Protective properties. Tumour cells proliferate by continuously ...
Pollutant carcinogens are missing from this document. Cancer Action NY contacted the Division of Cancer Prevention and Control (DCPC) regarding revising the Promotional Toolkit. The answer that we received was that the Toolkit would not be revised because it was no longer in use. The DCPC leads State Health Departments in the development and implementation of comprehensive cancer control plans. These plans are used by the health departments to provide direction to cancer burden reduction efforts at the state level. If the DCPC were to begin including pollutant carcinogen exposure reduction education among the cancer burden reduction endeavors that it promotes, the state health departments would follow this leadership and begin to provide such education to the general public. Cancer Action NY entered into a dialogue with Dr. Marcus Plescia, Director of the Division of Cancer Prevention and Control on the subject of dioxin exposure cancer risk reduction via dioxin exposure reduction education. At ...
[120 Pages Report] Check for Discount on Global Cancer Biomarkers Sales Market Report 2016 report by QYResearch Group. Notes: Sales, means the sales volume of Cancer Biomarkers Revenue,...
BioAssay record AID 902 submitted by NCGC: qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature.
Mitchell S. Cairo, M.D. ‌New York Medical College Chief, Pediatric Hematology, Oncology and Stem Cell Transplantation‌ Director, Children and Adolescent Cancer…
[PRESS INVITATION 21 February 2013] Karolinska Institutet invites you to a conference on the latest findings in cancer research, at which many of the worlds most influential scientists in the field will be talking about the microbiology behind cancer as well as cancer drugs and clinical studies.
Oncology/Anti-cancer drugs are used for treating various cancer types for improving and prolonging a patients survival time. Biological drugs, based on monoclonal antibodies (mAbs) would emerge as a preferred option for treating various cancer types, especially blood cancer (leukaemia). The rising incidence and prevalence of various cancer types, new cancer treatments and growing importance of biological and targeted drug therapies, are driving the market growth of LAMEA oncology/anti-cancer drugs. In addition, increasing demand of anti-cancer drugs for the treatment of ageing population, rising government funds and improved treatment results, are major factors boosting the market growth. However, the high cost involved in new drug development, coupled with threat of failure and adverse effects associated with anti-cancer drugs therapies, would restrain the growth of the LAMEA market. Moreover, accessibility of anti-cancer drugs incurred by high cost, is a major challenge that is expected to ...
Margaret Horton (pictured right) has a special connection with Cancer Council SA. Her mother, grandmother and great grandmother have all suffered through cancer, and her best friend is currently facing her own cancer battle.. Margaret is a passionate advocate for Cancer Council SA, volunteering at events including Daffodil Day and participating in fundraisers such as Girls Night In and Australias Biggest Morning Tea. She shares her reasons for leaving the ultimate gift towards a cancer free future.. I have seen my family go through three generations of breast cancer - my mum, my grandmother and my great grandmother. I have also seen my best friend (who I call my sister) fight her own breast cancer battle. I sat with her through her chemotherapy and shaved my head so she didnt feel alone when she lost all her hair. Nobody should have to go through this disease alone and I went with her because I love her and didnt want to see her struggle by herself. If you have seen someone close to you go ...
The ultimate goal of cancer research is the development of effective anticancer therapy. During the last several decades, the discovery of oncogenes, tumor suppressors, growth factors, signal transduction pathways has dramatically escalated our understanding of cancer cell biology and mechanisms of cell transformation.1-3 Hundreds of cellular proteins and pathways have been logically considered as molecular targets in a mechanism-based approaches of anticancer drug development.4-6 Yet, the progress in cancer treatment has not paralleled these dramatic achievements in basic research. ...
An international team of scientists in Japan, Switzerland, and the United States has confirmed that combining chemotherapy and immunotherapy in cancer treatment enhances the immune systems ability to find and eliminate cancer cells, even when the cancer-associated proteins targeted by the immune system are hidden behind the cancer cell membrane. In a study published online on February 8, 2012 in Cancer Research, the scientists show that antibodies, which have been successful in treating certain types of cancers, can effectively reach elusive intracellular targets, delaying tumor growth and prolonging survival when combined with chemotherapy. "The study provides proof-of-principle for a powerful new strategy that may greatly expand the arsenal of potential targets for cancer drug development and that could be broadly applicable to many different cancer types," said Dr. Hiroyoshi Nishikawa, a Cancer Research Institute (CRI)-funded associate professor in the Department of Experimental Immunology ...
Describe Activity Response, including but not limited to: Your response of resource use and effectiveness, participant response, etc.* ...
To appraise the feasibility of current adult medical and surgical techniques for ovarian preservation in pre-pubertal and adolescent girls with cancer. Literature search using PubMed and SCOPUS up to
Cancer is typically a consequence of imbalance between cell death and proliferation in a way favorable to cell proliferation and survival. Most conventional cancer therapies are based on targeting rapidly growing cancerous cells to block growth or enhance cell death, thereby, restoring the balance between these processes. In many instances, malignancies that develop resistance to current treatment modalities, such as chemotherapy, immunotherapy, and radiotherapy often present the greatest challenge in subsequent management of the patient. Studies have shown that under normal circumstances, cells utilize different death mechanisms, such as apoptosis (programmed cell death), autophagy, mitotic catastrophe, and necrosis to maintain homeostasis and physiological integrity of the organism, but these processes often appear to be altered in cancer. Thus, in recent years developing various strategies for administration of cytotoxic chemotherapeutics in combination with apoptosis-sensitizing reagents is
WASHINGTON, Sept. 30 (Xinhua) -- A clinical trial showed that the use of a bacterial spores had early efficacy and manageable toxicities in patients with treatment-refractory solid tumor malignancies.. "Even after a single injection of this bacterial therapy, we see biological and, in some patients, clinically meaningful activity," said Filip Janku, associate professor at the University of Texas MD Anderson Cancer Center.. Janku reported the findings on Sunday at the ongoing CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference from Sept. 30 to Oct. 3.. "This strategy is feasible, has manageable adverse effects, and could be clinically meaningful in patients with few therapeutic options," said Janku.. Unlike prior anticancer bacterial therapies that may cause infection and severe side effects, the bacteria called C. novyi-NT is an attenuated bacterium that requires a low-oxygen environment to survive and proliferate and therefore does not affect healthy cells, according to the ...
Belly fat has already been linked to an increased risk of heart disease and diabetes. Now research suggests it plays a role in certain cancers, as
Dear Friends,. I am buzzing off my hair in an event to raise money for children and their families fighting pediatric cancer. Its called the One Mission Kids Cancer Buzz-Off and will be held on Sunday, June 3, at Gillette Stadium. All proceeds will benefit Childrens Hospital Boston and the vital programs and services they provide to help kids beat cancer.. I have chosen to buzz off my hair because the toll pediatric cancer takes on patients and their families is profound. Children must endure painful treatments and lengthy hospital stays while their families cope with unimaginable stress, anxiety, and financial strain. Your generous support will assist One Mission in funding vital programs and services that bring help, hope, care and support to pediatric cancer patients and their families.. Donating through this website is simple, fast, and totally secure. It is also the most efficient way to support my fundraising efforts.. Many thanks for your support -- and dont forget to forward this to ...
Childhood cancer is rare. Childhood cancer arises from the primitive cells, thus the types of cancer found in children is significantly different than cancer in adults. And, because children are still growing they often have special physical and emotional needs. Childhood cancers tend to be more aggressive than adult cancers. Children are often treated at specialized Centers by team specialists who know the difference between childhood and adult cancers. The team specialists include pediatric oncologists, surgeons, radiation oncologists, pediatric oncology nurses and nurse practitioners. Childhood cancer typically refers to the type of cancer that affects the age groups from infancy to twenty one years old. However, it is possible for young adults to also develop a childhood cancer.
Cancer survival rates have doubled over the past 40 years due to the advances being made in research. Our support of cancer research has led to discoveries in many different cancers types including; breast, colorectal, prostate, leukaemia, oesophageal, ovarian, and lung among others. Some of our major successes are featured below.. Additionally, through our support of Cancer Trials Ireland, we can offer hope to cancer patients by providing them with access to treatments not currently available outside of the clinical research arena.. ...
Since cancer shares the same molecular machinery as the host, most therapeutic interventions which aim to target cancer would inadvertently also adversely affect the host. Additionally, cancer continuously evolves, streamlining its host-derived genome for a new single-celled existence. In particular, short-term clinical success observed with most antineoplastic therapies directly relate to the fact that cancer is constantly evolving. However, the clonal evolution of cancer occasionally also render cancer cells uniquely susceptible to therapeutic interventions, as is exemplified by the clinical relevance of synthetic lethality. Synthetic lethality describes a situation where the simultaneous loss of function in two genes results in lethality, but where a loss of function in either single gene is tolerated. This observation suggests that the evolution of cancer, usually seen as a major clinical challenge, may also afford a key opportunity in lowering on-target toxicities accosted with chemotherapy. As an
It is biochemically appropriate to consider that MUC13 consists of 2 distinct subunits, an extracellular α-subunit (consisting of the TR domain, 1 EGF-like domain, and a portion of the SEA domain) and a β-subunit (consisting of a portion of the SEA domain, 2 EGF-like domains, the TM domain, and the cytoplasmic tail, shown in Fig. 1). As described earlier, the SEA domain is predicted to contain a cleavage site and, although the amino acid sequence is unknown, there is biochemical evidence that MUC13 undergoes cleavage (9, 17). Williams and colleagues carried out a comprehensive Western blot analysis of MUC13 protein expressed in 2 cancer cell lines by using a polyclonal MUC13 antibody (9). In this experiment, under nonreducing conditions, MUC13 migrated as a 47-kDa band plus a 93-kDa band homodimer. In contrast, under reducing conditions, MUC13 appeared as a 58-kDa single band. The size difference observed with different conditions can be explained by the denaturation of MUC13 in the reducing ...
Overview. SEER is an authoritative source of information on cancer incidence and survival in the United States. SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 28 percent of the U.S. population.. Read Full Overview. ...
Meet Global Medical, Surgical and Radiation Oncologists from USA, Europe, Asia Pacific and Middle East at Cancer Conference, Oncology Conference, World Cancer Conference scheduled from November 27-28, 2017 Dubai, UAE
Not Beyond Us. This is the theme of World Cancer Day 2015. But how will we achieve it? Cancer can seem insurmountable. The global cancer burden is great. In 2012, 8.2 million people died from cancer-related causes-most of them in Africa, Asia, and Central and South America, which experiences more cases and more deaths than anywhere else: 60 percent of the 14 million new cancer cases annually and 70 percent of all cancer-related deaths occur in the developing world. The same countries bearing the brunt of the cancer burden have the fewest resources to tackle it.. Still we know and remind one another today, the 4th of February: We can and must stop vaccine-preventable cancers and reduce preventable cancer deaths. We must reduce the cancer inequities.. Cancer, you are not beyond us. Among women, cervical cancer is one of the deadliest -- and most easily preventable -- cancers. Women in the developing world account for 85 percent of the 270,000 deaths every year. Yet we know that effective ...
Since its inception, the primary focus area of our company has been oncology. Every year we expand our procurement network to include new clinical and research centers around the world in order to collect genetically-diverse human tumor specimens, including frozen tumor, tumor FFPE and matching blood products. Currently we manage human tumor tissue acquisition projects in Russia, Eastern Europe, India, the Philippines and the USA.
Beyond the misplaced reluctance of parents to have their children inoculated--or the lack of understanding of the importance of this for boys as well as girls--I wonder if part of the problem here is that insurance companies see no real payback in helping to promote this. After all, what is the chance that a child I am covering today with insurance is likely to be my subscriber by the time he or she gets cancer? Unlike polio, measles, and mumps, which show up during childhood, the head and neck cancers are not likely to show up until adulthood. While the cost per delivered dosage would be remarkably small, especially measured against the societal savings, there is currently no way to internalize that cost-benefit equation into insurance practice ...
Overview. SEER is an authoritative source of information on cancer incidence and survival in the United States. SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 28 percent of the U.S. population.. Read Full Overview. ...
Warburgs ideas are now making their way back into science. Once forgotten, they are being used to develop new approaches to cancer treatment. If it is extremely difficult to affect all the genetic factors that drive malignization, why not deprive cancer cells of the energy source they need so badly? Without nutrients, cancer cells will be unable to grow.. One more reason to take the Warburg hypothesis seriously again is that research has shown that the oncogenes involved in cell division also take part in regulation of nutrient consumption.. The focus on cancer metabolism could help develop ways to either block the genes responsible for the shift towards glucose consumption or prevent the cells from devouring glucose some other way. The problem is that cancer cells adapt fast. You take away glucose, they turn to glutamine, and so on.. As of this moment, it remains unclear whether the revived approach will yield significant results. One of the reasons for its possible failure is the diversity of ...
Gentaur molecular products has all kinds of products like :search , Biochai \ cDNA Panel _ Human Tumor Tissue, Same Tumor Type, Different Donors \ C8235543 for more molecular products just contact us
CHICAGO - The American Association for Cancer Research and the Kirk A. and Dorothy P. Landon Foundation will present three INNOVATOR Awards at the AACR Annual Meeting 2012, held here March 31 - April 4. The Fifth Annual Landon Foundation-AACR INNOVATOR Award for Cancer Prevention Research will be presented to Guang Peng, M.D., Ph.D., at…
TY - JOUR. T1 - Follow-Up Care Provider Preferences of Adolescent and Young Adult Cancer Survivors. AU - Ramsay, Joemy M.. AU - Mann, Karely. AU - Kaul, Sapna. AU - Zamora, Eduardo R.. AU - Smits-Seemann, Rochelle R.. AU - Kirchhoff, Anne C.. PY - 2018/4/1. Y1 - 2018/4/1. N2 - Purpose: To explore the experiences and perspectives of adolescent and young adult (AYA) cancer survivors regarding patient-provider relationships and their preferences surrounding type of healthcare provider for follow-up care. Methods: We recruited AYA cancer survivors who were diagnosed between the ages of 15 and 39 using the Utah Cancer Registry. Twenty-eight survivors participated in six focus groups held between March and May of 2015 in Salt Lake City and St. George, Utah. This analysis focuses on how survivors preferences about type of healthcare provider may influence their transition into, and utilization of, follow-up care. Results: On average, survivors were 6.3 (standard deviation = 1.7) years from their ...
TY - JOUR. T1 - Radiation-related new primary solid cancers in the childhood cancer survivor study. T2 - Comparative radiation dose response and modification of treatment effects. AU - Inskip, Peter D.. AU - Sigurdson, Alice J.. AU - Veiga, Lene. AU - Bhatti, Parveen. AU - Ronckers, Cécile. AU - Rajaraman, Preetha. AU - Boukheris, Houda. AU - Stovall, Marilyn. AU - Smith, Susan. AU - Hammond, Sue. AU - Henderson, Tara O.. AU - Watt, Tanya C.. AU - Mertens, Ann C.. AU - Leisenring, Wendy. AU - Stratton, Kayla. AU - Whitton, John. AU - Donaldson, Sarah S.. AU - Armstrong, Gregory T.. AU - Robison, Leslie L.. AU - Neglia, Joseph P.. PY - 2016/3/15. Y1 - 2016/3/15. N2 - Objectives The majority of childhood cancer patients now achieve long-term survival, but the treatments that cured their malignancy often put them at risk of adverse health outcomes years later. New cancers are among the most serious of these late effects. The aims of this review are to compare and contrast radiation dose-response ...
CLEVELAND, July 12, 2011 /PRNewswire/ -- In memory of their daughter, Angie, who died of melanoma at age 14, Char and Chuck Fowler have donated $17 million to establish The Angie Fowler Child & Young Adult Cancer Institute at University Hospitals (UH) Rainbow Babies & Childrens Hospital. Their daughters and sons-in-law, Chann and Ed Spellman and Holley and Rob Martens join them in making this transformational gift. (Photo: http://photos.prnewswire.com/prnh/20110712/CL33727 ). The largest individual donation in the history of UH Rainbow Babies & Childrens Hospital, the Fowlers lead gift will further the hospitals national leadership in childhood, adolescent and young adult cancers and blood disorders. The Angie Fowler Child & Young Adult Cancer Institute will include a new dedicated outpatient treatment facility and an expanded inpatient unit for pediatric and young adult patients, along with a rooftop garden at UH Rainbow Babies & Childrens Hospital.. "Char and Chuck Fowler, along with ...
1 From Memorial Sloan Kettering Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; The University of Texas MD Anderson Cancer Center; Massachusetts General Hospital Cancer Center; Stanford Cancer Institute; UCSF Helen Diller Family Comprehensive Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Fox Chase Cancer Center; Huntsman Cancer Institute at the University of Utah; Mayo Clinic Cancer Center; Roswell Park Cancer Institute; University of Michigan Comprehensive Cancer Center; Duke Cancer Institute; Consultant; Dana-Farber/Brigham and Womens Cancer Center; Fred & Pamela Buffett Cancer Center; City of Hope Comprehensive Cancer Center; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; University of Colorado Cancer Center; Vanderbilt-Ingram Cancer Center; UC San Diego Moores ...
Surgical oncology is the branch of surgery applied to oncology; it focuses on the surgical management of tumors, especially cancerous tumors. As one of several modalities in the management of cancer, the specialty of surgical oncology, before modern medicine the only cancer treatment with a chance of success, has evolved in steps similar to medical oncology (pharmacotherapy for cancer), which grew out of hematology, and radiation oncology, which grew out of radiology. The Ewing Society known today as the Society of Surgical Oncology was started by surgeons interested in promoting the field of oncology. Complex General Surgical Oncology was ratified by a specialty Board certification in 2011 from the American Board of Surgery. The proliferation of cancer centers will continue to popularize the field, as will developments in minimally invasive techniques, palliative surgery, and neo-adjuvant treatments. Whether surgical oncology constitutes a medical specialty per se is the topic of a heated ...
Acute Lymphoblastic Leukemia Treatment Acute Myeloid Leukemia Treatment Anal Cancer Treatment Basal Cell Carcinoma Treatment Bladder Cancer Treatment Bone & Spine Sarcoma Treatment Bone Cancer Treatment Brain Cancer Treatment Breast Cancer Treatment Cervical Cancer Treatment Chronic Lymphocytic Leukemia Treatment Chronic Myeloid Leukemia Treatment Colon Cancer Treatment Cranial Base Center Treatment Cutaneous Lymphoma Treatment Endocrine Cancers Treatment Endometrial Cancer Treatment Esophageal Cancer Treatment Gallbladder Cancer Treatment Gastrointestinal Cancers Treatment Gastrointestinal Carcinoid Tumors Treatment Genitourinary Cancers Treatment Gliomas Treatment Gynecologic Cancers Treatment Hairy Cell Leukemia Treatment Head & Neck Cancers Treatment Hemophilia Treatment Hodgkins Lymphoma Treatment Kaposi Sarcoma Treatment Kidney Cancer Treatment Laryngeal Cancer Treatment Leukemia Treatment Lip & Oral Cavity Cancer Treatment Liver Cancer Treatment Lung Cancers Treatment Lymphoma Treatment ...
Herbal medicine expert witnesses may opine on herbal medicine, acupuncture, and homeopathy. The Alternative Medicine Blog writes: Many children with cancer - April 15, 2010
Context. The Edmonton Symptom Assessment System (ESAS) is a brief, widely adopted, multidimensional questionnaire to evaluate patient-reported symptoms. Objectives. To develop a Korean version of the ESAS (K-ESAS) and to perform a psychometric analysis in Korean patients with advanced cancer. Methods. We tested the K-ESAS in two pilot studies with 15 patients each. We assessed internal consistency, test-retest reliability, and concurrent validity in 163 Korean patients, who completed the K-ESAS along with the Korean versions of the M. D. Anderson Symptom Inventory (K-MDASI) and the Hospital Anxiety and Depression Scale (K-HADS) twice. A total of 38 patients completed the questionnaires again seven days later to assess responsiveness. Results. The K-ESAS scores had good internal consistency, with a Cronbachs alpha coefficient of 0.88, indicating that no questions had undue influence on the score. Pearson correlation coefficients for K-ESAS symptom scores between baseline and after two to four ...
Full Text CA-96-016 MINORITY-BASED COMMUNITY CLINICAL ONCOLOGY PROGRAM NIH GUIDE, Volume 25, Number 20, June 21, 1996 RFA: CA-96-016 P.T. 34, FF Keywords: Autoimmunity Oncology Disease Prevention+ Treatment, Medical+ Clinical Trial National Cancer Institute Letter of Intent Receipt Date: August 7, 1996 Application Receipt Date: September 25, 1996 PURPOSE The Division of Cancer Prevention and Control (DCPC), National Cancer Institute (NCI), is continuing the established cancer control effort, which involves practicing oncologists who serve large minority populations in the NCI clinical trials program. The Community Oncology and Rehabilitation Branch (CORB), DCPC, invites applications from domestic institutions with greater than 50 percent of new cancer patients from minority populations for cooperative agreements in response to this Minority-Based Community Clinical Oncology Program (Minority-Based CCOP) Request for Applications (RFA). Applicants for new and currently funded Minority-Based CCOPs ...